Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 16, 2018
Kamada Announces the End of the Labor Strike in the Company’s Manufacturing Facility; All Employees Returned to Work
REHOVOT, Israel, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that on August 15, 2018, the ...
August 16, 2018
VBL Therapeutics Announces Second Quarter 2018 Financial Results
TEL AVIV, Israel, Aug. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) today announced financial results for the second quarter ended June 30, 2018 and ...
August 16, 2018
BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will be presenting a poster at ...
August 16, 2018
Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors
HOPKINTON, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
August 15, 2018
Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
August 15, 2018
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic ...
August 15, 2018
HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel
TUCSON, Ariz., Aug. 15, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, ...
August 13, 2018
ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
ArQule, Inc. (ARQL), today announced the publication of preclinical study data for ARQ 531, the Company’s rationally-designed, reversible inhibitor of both wild type and C481S-mutant ...
August 13, 2018
Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
NEWTON, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
August 13, 2018
Achaogen to Present at the Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
August 13, 2018
STRATA Skin Sciences Reports Second Quarter 2018 Financial Results
HORSHAM, Pa., Aug. 13, 2018 (GLOBE NEWSWIRE) -- (SSKN) STRATA Skin Sciences, Inc. (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
August 13, 2018
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
LIVONIA, Mich., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
August 13, 2018
Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
August 13, 2018
Basilea reports on first Cresemba® approval in MENA region
Basel, Switzerland, August 13, 2018 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that its partner Hikma Pharmaceuticals LLC, gained regulatory approval for the antifungal Cresemba® ...
August 13, 2018
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
August 13, 2018
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags
BUFFALO, N.Y., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
August 13, 2018
Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency
NEW YORK and MEMPHIS, Tenn., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development ...
August 13, 2018
Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
August 13, 2018
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
August 13, 2018
Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif., Aug. 13, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion ...
Page 32 of 127